Holen Sie sich die Stockscreener-App
1.59
1.46%
-0.02
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Gains Report: What is Acrivon Therapeutics Incs 5 year growth outlookWeekly Risk Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acrivon Therapeutics Highlights ACR-368’s ~50% Response in Serous Endometrial Cancer at TD Cowen Conf. - Defense World
Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan
Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares - Stock Titan
Executive Mary Miller at Acrivon Therapeutics (ACRV) granted 129,760 options - Stock Titan
Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares - Stock Titan
Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan
Acrivon Therapeutics (ACRV) grants stock options to CEO and EVP - Stock Titan
ACRV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acrivon Therapeutics, Inc. (ACRV) Raised to Buy: Discover the Reasons - Bitget
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Yahoo Finance
Jefferies reiterates Acrivon Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com
Acrivon Therapeutics (NASDAQ: ACRV) takes full control of ACR-368 OncoSignature - Stock Titan
What is HC Wainwright’s Estimate for ACRV FY2030 Earnings? - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - Defense World
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com Canada
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan
Pullback Watch: Can Acrivon Therapeutics Inc expand into new marketsRate Hike & Reliable Breakout Forecasts - baoquankhu1.vn
Acrivon Therapeutics (ACRV) insiders detail RSU tax-related share withholding - Stock Titan
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 - GlobeNewswire
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - Bitget
Why Acrivon Therapeutics Inc. stock is considered a top pickMarket Growth Report & Risk Managed Investment Strategies - mfd.ru
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen - Defense World
ACRV Stock Price, Forecast & Analysis | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
Market Review: Is Acrivon Therapeutics Inc showing insider buyingPrice Action & Verified Momentum Watchlists - baoquankhu1.vn
[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity - Stock Titan
ACRVAcrivon Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - The Manila Times
Acrivon Therapeutics Strengthens its Precision Medicine - GlobeNewswire
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Trading Recap: What is Acrivon Therapeutics Incs 5 year growth outlookRecession Risk & Stock Portfolio Risk Management - baoquankhu1.vn
ACRV Should I Buy - Intellectia AI
Can Acrivon Therapeutics Inc. expand into new marketsQuarterly Risk Review & Risk Controlled Stock Alerts - mfd.ru
Reviewing Acrivon Therapeutics (NASDAQ:ACRV) & Innate Pharma (OTCMKTS:IPHYF) - Defense World
Why Acrivon Therapeutics Inc. stock is a value investor pickWeekly Risk Summary & AI Powered Buy/Sell Recommendations - mfd.ru
Trade Recap: Is Acrivon Therapeutics Inc showing insider buying2025 Sector Review & Smart Swing Trading Alerts - baoquankhu1.vn
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Is Acrivon Therapeutics Inc. showing insider buying2025 Major Catalysts & Smart Investment Allocation Tips - mfd.ru
Short Squeeze: Why is Ameriprise Financial Inc stock going upJuly 2025 Rallies & Weekly High Momentum Picks - baoquankhu1.vn
Winners Losers: Will Acrivon Therapeutics Inc benefit from green energy policiesShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
Activity Recap: Is Acrivon Therapeutics Inc a good ESG investmentQuarterly Earnings Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $11.67 - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):